Medtide

Medtide Debt

The Debt of Medtide (3880.HK) as of Nov 19, 2026 is 680.57 M CNY. In the previous year, Debt was 542.04 M CNY — a change of 25.56% (higher).

Debt

680.57 MCNY

YoY

25.56%

Last updated:

In 2024, Medtide's total debt was 680.57 M CNY, a 25.56% change from the 542.04 M CNY total debt recorded in the previous year.

The Medtide Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2021
300.00 M CNY
Jan 1, 2022
519.48 M CNY
Jan 1, 2023
542.04 M CNY
Jan 1, 2024
680.57 M CNY
The Medtide Debt history
YEARDebtYoY
680.57 MCNY+25.56%
542.04 MCNY+4.34%
519.48 MCNY+73.16%
300.00 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medtide Stock analysis

What does Medtide do? Medtide, Inc. generates revenue through peptide-focused contract research, development, and manufacturing services. The company offers CRO services for peptide new chemical entity (NCE) discovery and synthesis, alongside CDMO services covering peptide chemistry, manufacturing, and control (CMC) development and commercial production. Its primary clients are pharmaceutical companies seeking active pharmaceutical ingredients (APIs) rather than finished drug products, with services delivered across domestic and overseas markets. The firm's revenue streams are derived from these specialized peptide-related R&D and manufacturing contracts. Medtide's business model centers on providing comprehensive peptide development and manufacturing solutions, including CMC filing support for clients. The company's services target the API segment of the pharmaceutical industry, focusing on peptide-based drug development rather than final drug formulations. This specialization allows Medtide to serve clients requiring high-quality peptide synthesis and manufacturing capabilities for their drug development pipelines. The company's revenue is generated through direct contracts with pharmaceutical firms for peptide-related services, including discovery synthesis, CMC development, and commercial manufacturing. These services are delivered to clients operating in both domestic and international markets, with the firm emphasizing its expertise in peptide chemistry and manufacturing processes. Medtide's business model relies on its ability to provide end-to-end peptide development and manufacturing solutions to pharmaceutical clients. Medtide is one of the most popular companies on Eulerpool.

Debt Details

Understanding Medtide's Debt Structure

Medtide's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Medtide's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Medtide’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Medtide’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Medtide stock

Debt of Medtide is 680.57 M CNY in 2024.

Debt of Medtide changed from 542.04 M CNY to 680.57 M CNY, representing a 25.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Medtide since 2006 – with annual values, charts, and detailed analysis.

Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Medtide historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Medtide

All Key Metrics — Medtide